The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Conference: ASGCT Annual Meeting, 2022

2022-05-20T09:29:29-04:00Cell & Gene Therapy, Thought Leadership|

Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.


Article: Cell & Gene Therapies: Opportunities for Innovation

2022-05-20T09:22:09-04:00Cell & Gene Therapy, Thought Leadership|

In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.


On-Demand Podcast: Foundations of Flexible Manufacturing

2021-11-30T09:04:31-05:00Cell & Gene Therapy, Thought Leadership|

Is “flexible manufacturing” just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit? Business of Biotech Podcast: Episode 69, “Foundations of Flexible Manufacturing” features insights from Tony Khoury (EVP of Project Farma) and Brian Winstead (Senior Director, Facilities & Engineering at Sarepta Therapeutics) on what flexible manufacturing means, when it works and when it doesn’t.


On-Demand Podcast: The CDMO Capacity Crunch

2021-11-04T13:21:57-04:00Cell & Gene Therapy, Thought Leadership|

Business of Biotech Podcast: Episode 68, “The CDMO Capacity Crunch” features insights from Anshul Mangal (President of Project Farma and Precision ADVANCE), Audrey Greenberg (Co-founder of Discovery Labs), and Sumit Verma (SVP, Commercial Manufacturing at Iovance) on CDMO buildouts, limited manufacturing space, and the expertise needed to meet timelines, satisfy investors, and drive competitive advantage.


Load More Posts